Login to Your Account



Pharma: Other News To Note


Tuesday, July 10, 2012
• Eli Lilly and Co., of Indianapolis, and Bristol-Myers Squibb Co., of New York, said Erbitux (cetuximab) in combination with chemotherapy regimen Folfiri (irinotecan, 5-fluorouracil, leucovorin) is the first biologic treatment regimen in nearly a decade to receive FDA approval for newly diagnosed metastatic colorectal cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription